JW Pharma unveils S.Korea's first homegrown hybrid incubator

The models from the company's Hi-Mammi brand have entered a domestic market dominated by imports

JW Pharma unveils S.Korea's first homegrown hybrid incubator
Ji-Hyun Lee 1
2023-06-29 12:22:03 bluesky@hankyung.com
Bio & Pharma

South Korea's JW Pharmaceutical on Wednesday released three products from its new incubator brand Hi-Mammi.

The company's rollout of hybrid and high- and low-end models was its first product launch since acquiring the medical device unit of affiliate JW Bioscience in January.

The Hi-Mammi incubator simulates the environment of the mother's body to help the development of a premature baby of a certain weight or a newborn with abnormal symptoms. The hybrid model needs higher technology because the proper temperature must be maintained with a heating device even when the top panel is open.

JW Pharmaceutical is South Korea's first to produce and launch a domestically developed hybrid incubator.

The domestic incubator market for front-line medical institutions has shifted toward one combining closed and open types, but no domestic company had made its own before JW Pharmaceutical. This has allowed just three companies – GE Healthcare Technologies of the US, Atom Medical of Japan and Drager Medical of Germany – to control over 90% of the domestic market.

The Hi-Mammi incubators are designed to support a newborn's mental stability through a built-in speaker that transmits the mother's heartbeat or voice into the compartment through a smartphone or MP3 player.

The family screen shows the infant's treatment status at a glance and displays family photos or messages of encouragement. Other features are full-body imaging of a baby and stronger soundproofing to minimize stress from noise.

In addition, JW Pharmaceutical will develop an artificial intelligence-based smart care system using deep learning technology grounded in clinical data to create a customized environment for neonatal intensive care.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#JW Pharmaceutical #incubator #Hi-Mammi #hybrid incubator #homegrown

JW Pharma to use zebrafish in new drug development

JW Pharma to use zebrafish in new drug development

South Korean drug developer JW Pharmaceutical has entered into a memorandum of understanding (MOU) with Zefit, a domestic non-clinical trial institute that specializes in zebrafish models, to expedite the development of new drugs, the company said on Monday. As per the agreement, JW Pharmaceut

JW Pharma receives 1st overseas patent for its hair loss treatment

JW Pharma receives 1st overseas patent for its hair loss treatment

JW Pharmaceutical's headquarters JW Pharmaceutical, a drug company based in South Korea, has received its first patent for a hair loss treatment that is currently in development. This marks the first time that its candidate drug has been patented overseas. JW received on Monday a patent for JW0

JW Pharma to put AI into new drug ingredient development

JW Pharma to put AI into new drug ingredient development

South Korea's drug developer JW Pharmaceutical is expanding the scope of its artificial intelligence (AI) uses from new drug research to the development of active pharmaceutical ingredients (APIs).JW Pharmaceutical said on Monday that it has signed an agreement with Merck Life Science to resea

JW Pharma applies for phase 3 trial in Taiwan for gout treatment

JW Pharma applies for phase 3 trial in Taiwan for gout treatment

JW Pharmaceutical headquarters JW Pharmaceutical announced through its disclosure on Monday that it had applied last Friday for a phase 3 trial for Epaminurad, a gout treatment, with the Taiwan Food and Drug Authority (TFDA).Epaminurad is an investigational oral uric acid transporter-1 (URAT1)

(* comment hide *}